AMBS Opinions 08/10/2014 00:27:31 $AMBS
first I am not your friend, you gave up that right at the first lie.
and if they were 4 months away from
Quote:
A 500 MILLION DOLLAR A YEAR OPPORTUNITY.
they would not need to increase the shares
I know the difference but do you?
I know how to read a financial statement!
I know the company has $875 cash!!!
AMBS is broke so where are they getting money to continue operations?
They get it from paying for promotion to raise the stock price so they can sell for cash.
how can they sell shares they don't have, they raise the Authorized to give them availability
By the end of the year my friend.
when? when will it be a 500 MILLION DOLLAR A YEAR OPPORTUNITY?
10 years? 20? in our lifetime?
Quote:
HE COMPANY HAS STATED LYMPRO IS A 500 MILLION DOLLAR A YEAR OPPORTUNITY.
on your word???? AMBS going to .15 or is Gerald giving you a price target?
Share holders like the idea of 2 billion shares available on the the market?
seems to me like double 0's is more likely
THE COMPANY HAS STATED LYMPRO IS A 500 MILLION DOLLAR A YEAR OPPORTUNITY.
.15 cents by the end of the week.I smell NEWS.
yep, AMBS is not going anywhere, anyttime soon, no moon rockets coming. you have years to wait and watch until AMBS continues to drop on pps, maybe even a reverse split in your near future
don't sell. keep buying!!!
Lympro is going to come out and you all will be chasing this stock.
The Wolf Says
LymPro is for Real...
"I agree to disagree you understand..." Wolfman Jack...Michael J. Fox won't let the wolf down.. "You are the reason I'm Sneezin" and "If I'm lI'm dying"....I don't see any disagreement that can't be resolved.. Have Mercy Have Merger you understand...imo Wolf ahooooooooooooooooooooooooooooooooooooooooooooo
Back to the Future for 2015, the 30th anniversary of the movie
and for AMBS...
YOU SAID
Aim High Profits News
Search this website
HomeAim High Profits News AMBS | Amarantus and MJFF Disagreement Could Cost Big
AMBS | Amarantus and MJFF Disagreement Could Cost Big
AMBS Stock, Amarantus BioSciences Inc.Although Gerald Commissiong, President & CEO of Amarantus BioSciences Inc. (AMBS), wasn’t the best Running Back while at Stanford, the PR “fumble” could be costly. Although they timed the good news with Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp. (RBCC), to come out before the market opened, they waited til the final whistle blew to close the markets for the week before letting the bad news out. With the after market news that The Michael J. Fox Foundation basically threw the Wednesday PR under the bus, AMBS stock will be expected to start with a penalty before the Monday morning kickoff.
wow what a great company AMBS is,
look no revenues 2 years in a row and very little prior years
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue - - 224 192
Cost of Revenue - - - -
Gross Profit - - 224 192
and now the A/S is to be raised to 2 BILLION
and you deny promoting AMBS, wow
Wow. Posting something from 2 years ago. Lol. Looks like everyone knows your agenda.
I ASSURE YOU I AM NOT A PROMOTER. I watched PHOT go up to .77 with 2 billion outstanding.
Lympro is going to be a hot product. Once the big diagnostic companies start buying Lympro this stock will trade at 1.00.
many watchers/followers will wait and let this play out before re-entry
you get that directly from the company? how can you smell news?
or is that just an off topic remark from a promoter?
I smell NEWS.
Gr8 Post and Gr8 Analysis Solantey.. I know one fact..William Gartner has gr8 contacts with QuestDx in Phoenix area..But not sure of collaboration with LP with Sonora Quest Labs before AMBS came into the picture in 2012,,,....imo Wolf ... a William Gartner fan you understand..ahooooooooooooooooooooooooooooooo
http://www.sonoraquest.com/?AspxAutoDetectCookieSupport=1
Sonora Quest Laboratories - Diagnostic Lab Tests | Arizona .
*****************************************************************
http://www.reuters.com/article/2008/03/03/idU...BW20080303
Sonora Quest Laboratories to Provide Phlebotomy Services
PHOENIX--(Business Wire)--
Provista Life Sciences LLC and Sonora Quest Laboratories announced
today a collaborative effort that will allow doctors and patients
seeking to obtain Provista Life Science's BT Test(TM) for breast
cancer access to several strategically located Sonora Quest
Laboratories phlebotomy service facilities throughout Arizona.
Provista Life Sciences, a Phoenix-based diagnostic development and
commercialization company, recently announced the availability of its
Biomarker Translation Test (BT Test), a blood test specifically
designed to assist physicians and other healthcare providers in making
an earlier and more accurate diagnosis of breast cancer when used in
conjunction with mammography.
"We are thoroughly impressed with the management and staff at
Sonora Quest Laboratories and their willingness to assist and support
our efforts to make our BT Test more readily accessible to the
public," says William J. Gartner, CEO and President of Provista Life
Sciences. "Until now, doctors prescribing the test and patients
wishing to take the BT Test were limited to our central Phoenix
laboratory, Provista Diagnostics, for their blood draws. With Sonora
Quest's support, we can now make the BT Test more readily accessible
to women across all of Arizona."
Patients wanting the BT Test will need to obtain a prescription
from their provider. With a prescription in hand, patients will be
directed to Provista Diagnostics' Web site (www.ProvistaDx.com) for
instruction on how to complete the ordering process, pay for the test
and download a blood Draw Authorization Form. The Draw Authorization
Form will direct the patients to an approved Sonora Quest Laboratories
or Provista Diagnostics blood draw center. Patients who prefer not to
go online, or who do not have Internet access, can go directly to
Provista Diagnostics' laboratory to complete this process and have
their blood drawn.
"We are extremely pleased to assist Provista Life Sciences in
their efforts to make the BT Test more accessible to the women in
Arizona," stated Joyce Santis, Chief Operating Officer for Sonora
Quest Laboratories. "We recognize the importance of making public
access as easy as possible in this regard, and we are glad we can play
a role in making that happen."
About Sonora Quest Laboratories
Sonora Quest Laboratories is an integrated laboratory system
servicing over 6,000 clients throughout Arizona, including hospitals,
physicians, managed care organizations and employers. They have more
than 2,000 employees statewide, and perform over 60,000 diagnostic
tests per day. For more information, please visit www.sonoraquest.com
or call 602-685-5285.
Provista Life Sciences' Background
Provista Life Sciences was established in 2006 as a biotechnology
development and commercialization organization that provides the
scientific and operating management resources to rapidly advance the
development and introduction of novel diagnostics technologies into
the domestic and global marketplace.
******************************************************************
Solantey Member Level Saturday, 08/09/14 01:28:13 PM
Re: None
Post # of 107398
Think Positive
Gerald stated that the LymPro partnership and the up-listing are still "on track" and that nothing has changed.
What if the partner for LymPro is a company such as Johnson & Johnson or Quest Diagnostics who is asking for an ownership position and a seat or two on the board of directors. Suppose they purchase 50,000,000 shares at .50 share as the basis for an "up-front cash payment" of $25,000,000.
Obviously the numbers could be different but this scenario makes perfect sense.
In regards to increasing the share count to have additional shares available one approach is "it's better to have them and not need them than to need them and not have them". To a small cap company such as $AMBS additional shares are similar to having a line of credit.
Monday will be interesting. Let's see what Gerald has to say.
Nothing more to say until after I read Gerald's blog.
Have a great weekend!!!
Twitter: @AmarantusBio .... 10,000+ followers.
Aim High Profits News
Search this website
HomeAim High Profits News AMBS | Amarantus and MJFF Disagreement Could Cost Big
AMBS | Amarantus and MJFF Disagreement Could Cost Big
AMBS Stock, Amarantus BioSciences Inc.Although Gerald Commissiong, President & CEO of Amarantus BioSciences Inc. (AMBS), wasn’t the best Running Back while at Stanford, the PR “fumble” could be costly. Although they timed the good news with Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp. (RBCC), to come out before the market opened, they waited til the final whistle blew to close the markets for the week before letting the bad news out. With the after market news that The Michael J. Fox Foundation basically threw the Wednesday PR under the bus, AMBS stock will be expected to start with a penalty before the Monday morning kickoff.
is GC still 32? he never ages in the filings..
my post was not off topic and review will be requested. AMBS has been promoted and continues to be promoted. Shame that AMBS felt the need to increase the authorized shares. Not good for shareholders
first I am not your friend, you gave up that right at the first lie.
and if they were 4 months away from
Quote:
A 500 MILLION DOLLAR A YEAR OPPORTUNITY.
they would not need to increase the shares
I know the difference but do you?
I know how to read a financial statement!
I know the company has $875 cash!!!
AMBS is broke so where are they getting money to continue operations?
They get it from paying for promotion to raise the stock price so they can sell for cash.
how can they sell shares they don't have, they raise the Authorized to give them availability
By the end of the year my friend.
when? when will it be a 500 MILLION DOLLAR A YEAR OPPORTUNITY?
10 years? 20? in our lifetime?
Quote:
HE COMPANY HAS STATED LYMPRO IS A 500 MILLION DOLLAR A YEAR OPPORTUNITY.
on your word???? AMBS going to .15 or is Gerald giving you a price target?
Share holders like the idea of 2 billion shares available on the the market?
seems to me like double 0's is more likely
THE COMPANY HAS STATED LYMPRO IS A 500 MILLION DOLLAR A YEAR OPPORTUNITY.
.15 cents by the end of the week.I smell NEWS.
yep, AMBS is not going anywhere, anyttime soon, no moon rockets coming. you have years to wait and watch until AMBS continues to drop on pps, maybe even a reverse split in your near future
don't sell. keep buying!!!
Lympro is going to come out and you all will be chasing this stock.
The Wolf Says
LymPro is for Real...
"I agree to disagree you understand..." Wolfman Jack...Michael J. Fox won't let the wolf down.. "You are the reason I'm Sneezin" and "If I'm lI'm dying"....I don't see any disagreement that can't be resolved.. Have Mercy Have Merger you understand...imo Wolf ahooooooooooooooooooooooooooooooooooooooooooooo
Back to the Future for 2015, the 30th anniversary of the movie
and for AMBS...
YOU SAID
Aim High Profits News
Search this website
HomeAim High Profits News AMBS | Amarantus and MJFF Disagreement Could Cost Big
AMBS | Amarantus and MJFF Disagreement Could Cost Big
AMBS Stock, Amarantus BioSciences Inc.Although Gerald Commissiong, President & CEO of Amarantus BioSciences Inc. (AMBS), wasn’t the best Running Back while at Stanford, the PR “fumble” could be costly. Although they timed the good news with Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp. (RBCC), to come out before the market opened, they waited til the final whistle blew to close the markets for the week before letting the bad news out. With the after market news that The Michael J. Fox Foundation basically threw the Wednesday PR under the bus, AMBS stock will be expected to start with a penalty before the Monday morning kickoff.
wow what a great company AMBS is,
look no revenues 2 years in a row and very little prior years
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue - - 224 192
Cost of Revenue - - - -
Gross Profit - - 224 192
and now the A/S is to be raised to 2 BILLION
and you deny promoting AMBS, wow
Wow. Posting something from 2 years ago. Lol. Looks like everyone knows your agenda.
I ASSURE YOU I AM NOT A PROMOTER. I watched PHOT go up to .77 with 2 billion outstanding.
Lympro is going to be a hot product. Once the big diagnostic companies start buying Lympro this stock will trade at 1.00.
many watchers/followers will wait and let this play out before re-entry
you get that directly from the company? how can you smell news?
or is that just an off topic remark from a promoter?
I smell NEWS.
Gr8 Post and Gr8 Analysis Solantey.. I know one fact..William Gartner has gr8 contacts with QuestDx in Phoenix area..But not sure of collaboration with LP with Sonora Quest Labs before AMBS came into the picture in 2012,,,....imo Wolf ... a William Gartner fan you understand..ahooooooooooooooooooooooooooooooo
http://www.sonoraquest.com/?AspxAutoDetectCookieSupport=1
Sonora Quest Laboratories - Diagnostic Lab Tests | Arizona .
*****************************************************************
http://www.reuters.com/article/2008/03/03/idU...BW20080303
Sonora Quest Laboratories to Provide Phlebotomy Services
PHOENIX--(Business Wire)--
Provista Life Sciences LLC and Sonora Quest Laboratories announced
today a collaborative effort that will allow doctors and patients
seeking to obtain Provista Life Science's BT Test(TM) for breast
cancer access to several strategically located Sonora Quest
Laboratories phlebotomy service facilities throughout Arizona.
Provista Life Sciences, a Phoenix-based diagnostic development and
commercialization company, recently announced the availability of its
Biomarker Translation Test (BT Test), a blood test specifically
designed to assist physicians and other healthcare providers in making
an earlier and more accurate diagnosis of breast cancer when used in
conjunction with mammography.
"We are thoroughly impressed with the management and staff at
Sonora Quest Laboratories and their willingness to assist and support
our efforts to make our BT Test more readily accessible to the
public," says William J. Gartner, CEO and President of Provista Life
Sciences. "Until now, doctors prescribing the test and patients
wishing to take the BT Test were limited to our central Phoenix
laboratory, Provista Diagnostics, for their blood draws. With Sonora
Quest's support, we can now make the BT Test more readily accessible
to women across all of Arizona."
Patients wanting the BT Test will need to obtain a prescription
from their provider. With a prescription in hand, patients will be
directed to Provista Diagnostics' Web site (www.ProvistaDx.com) for
instruction on how to complete the ordering process, pay for the test
and download a blood Draw Authorization Form. The Draw Authorization
Form will direct the patients to an approved Sonora Quest Laboratories
or Provista Diagnostics blood draw center. Patients who prefer not to
go online, or who do not have Internet access, can go directly to
Provista Diagnostics' laboratory to complete this process and have
their blood drawn.
"We are extremely pleased to assist Provista Life Sciences in
their efforts to make the BT Test more accessible to the women in
Arizona," stated Joyce Santis, Chief Operating Officer for Sonora
Quest Laboratories. "We recognize the importance of making public
access as easy as possible in this regard, and we are glad we can play
a role in making that happen."
About Sonora Quest Laboratories
Sonora Quest Laboratories is an integrated laboratory system
servicing over 6,000 clients throughout Arizona, including hospitals,
physicians, managed care organizations and employers. They have more
than 2,000 employees statewide, and perform over 60,000 diagnostic
tests per day. For more information, please visit www.sonoraquest.com
or call 602-685-5285.
Provista Life Sciences' Background
Provista Life Sciences was established in 2006 as a biotechnology
development and commercialization organization that provides the
scientific and operating management resources to rapidly advance the
development and introduction of novel diagnostics technologies into
the domestic and global marketplace.
******************************************************************
Solantey Member Level Saturday, 08/09/14 01:28:13 PM
Re: None
Post # of 107398
Think Positive
Gerald stated that the LymPro partnership and the up-listing are still "on track" and that nothing has changed.
What if the partner for LymPro is a company such as Johnson & Johnson or Quest Diagnostics who is asking for an ownership position and a seat or two on the board of directors. Suppose they purchase 50,000,000 shares at .50 share as the basis for an "up-front cash payment" of $25,000,000.
Obviously the numbers could be different but this scenario makes perfect sense.
In regards to increasing the share count to have additional shares available one approach is "it's better to have them and not need them than to need them and not have them". To a small cap company such as $AMBS additional shares are similar to having a line of credit.
Monday will be interesting. Let's see what Gerald has to say.
Nothing more to say until after I read Gerald's blog.
Have a great weekend!!!
Twitter: @AmarantusBio .... 10,000+ followers.
Aim High Profits News
Search this website
HomeAim High Profits News AMBS | Amarantus and MJFF Disagreement Could Cost Big
AMBS | Amarantus and MJFF Disagreement Could Cost Big
AMBS Stock, Amarantus BioSciences Inc.Although Gerald Commissiong, President & CEO of Amarantus BioSciences Inc. (AMBS), wasn’t the best Running Back while at Stanford, the PR “fumble” could be costly. Although they timed the good news with Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp. (RBCC), to come out before the market opened, they waited til the final whistle blew to close the markets for the week before letting the bad news out. With the after market news that The Michael J. Fox Foundation basically threw the Wednesday PR under the bus, AMBS stock will be expected to start with a penalty before the Monday morning kickoff.
is GC still 32? he never ages in the filings..
my post was not off topic and review will be requested. AMBS has been promoted and continues to be promoted. Shame that AMBS felt the need to increase the authorized shares. Not good for shareholders
